ArticleScientific reports2025
Asterias amurensis lipids enhance the immunity of immunosuppressed mice as sustainable marine-eco materials.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune effects of lipids isolated fromFrontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Starfish (Asterias amurensis) are important predators in the marine benthic environment, preying on mollusks and echinoderms. Their waste also causes significant environmental harm. However, starfish contain a variety of nutrients and biologically active compounds that require further investigation. To maintain marine ecosystems and address environmental waste, lipids were extracted from A. amurensis skin, and their immune-enhancing effects were evaluated in cyclophosphamide (CY)- induced immunosuppressive mice. A. amurensis lipids were combined with PEG 6000 (AA-PEG), which contains a high content of polyunsaturated fatty acids (PUFAs, 49.44%), primarily C20:5n3. Mice were administered various dosages of AA-PEG, ranging from 50 to 200 mg/kg body weight (BW) via oral delivery and CY injection. Results revealed that AA-PEG at 150 mg/kg BW promoted the recovery of cellular immune function in both splenocytes from the spleen and peritoneal macrophages, similar to the normal group. Administration of AA-PEG (50-150 mg/kg BW) gradually raised the spleen index (2.2-2.5 mg/g) and natural killer (NK) cell activity (91-102%), and enhanced ConA- or LPS-stimulated splenocyte proliferation. Subsets of T -lymphocytes (CD4 + and CD8+) does-dependently increased by AA-PEG. The phagocytic capacity (58-82%) and proliferation (69-98%) of peritoneal macrophages, which had been reduced by CY, were restored with AA-PEG. AA-PEG boosts immunity by promoting nitric oxide (NO) generation (84-103%). Furthermore, AA-PEG has been shown to increase immune-related cytokines in splenocytes and peritoneal macrophages, indicating a potential enhancement of Th1 and Th2 activity. These results suggest that AA-PEG restored the immune function of immunosuppressed mice and could be used as an effective immunomodulatory agent, which may play a crucial role in maintaining environmental sustainability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.